Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors

In 2015, the first large-scale placebo-controlled trial designed to assess cardiovascular safety of glucose-lowering with sodium–glucose co-transporter 2 (SGLT2) inhibition in type 2 diabetes mellitus raised hypotheses that the class could favourably modify not only risk of atherosclerotic cardiovas...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Herrington, WG, Savarese, G, Haynes, R, Marx, N, Mellbin, L, Lund, LH, Dendale, P, Seferovic, P, Rosano, G, Staplin, N, Baigent, C, Cosentino, F
Formatua: Journal article
Hizkuntza:English
Argitaratua: Wiley 2021

Antzeko izenburuak

Antzeko izenburuak